Listed

ImmunityBio, Inc.

IBRXNasdaqCIK 1326110HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$51.2m, Q2 FY2026
Operating income−$61.7m, Q2 FY2026
Net income−$230.4m, Q2 FY2026
ImmunityBio, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.1Revenue, Q3 FY2023, three months to 2023-09-30$82.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure0.1Revenue, Q4 FY2023, three months to 2023-12-31$139.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$40.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure1.0Revenue, Q2 FY2024, three months to 2024-06-30$1.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure6.1Revenue, Q3 FY2024, three months to 2024-09-30$6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure7.6Revenue, Q4 FY2024, three months to 2024-12-31$7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure16.5Revenue, Q1 FY2025, three months to 2025-03-31$16.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure26.4Revenue, Q2 FY2025, three months to 2025-06-30$26.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure32.1Revenue, Q3 FY2025, three months to 2025-09-30$32.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure38.3Revenue, Q4 FY2025, three months to 2025-12-31$38.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure44.2Revenue, Q1 FY2026, three months to 2026-03-31$44.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure51.2Revenue, Q2 FY2026, three months to 2026-06-30$51.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Cost of revenue$m0.0Cost of revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure0.0Cost of revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure0.0Cost of revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure0.0Cost of revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure0.0Cost of revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure0.0Cost of revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure0.1Cost of revenue, Q1 FY2025, three months to 2025-03-31$58.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure0.1Cost of revenue, Q2 FY2025, three months to 2025-06-30$136.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure0.2Cost of revenue, Q3 FY2025, three months to 2025-09-30$177.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure0.4Cost of revenue, Q4 FY2025, three months to 2025-12-31$382.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure0.2Cost of revenue, Q1 FY2026, three months to 2026-03-31$238.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure0.3Cost of revenue, Q2 FY2026, three months to 2026-06-30$298.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Research and development$m48.4Research and development, Q3 FY2023, three months to 2023-09-30$48.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure51.5Research and development, Q4 FY2023, three months to 2023-12-31$51.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-03, accession 0001326110-25-000033. Derived: 12-month figure less the 9-month figure.Report this figure53.4Research and development, Q1 FY2024, three months to 2024-03-31$53.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-05-09, accession 0001326110-24-000064.Report this figure51.1Research and development, Q2 FY2024, three months to 2024-06-30$51.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-08-12, accession 0001326110-24-000103.Report this figure50.4Research and development, Q3 FY2024, three months to 2024-09-30$50.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure35.2Research and development, Q4 FY2024, three months to 2024-12-31$35.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-03, accession 0001326110-25-000033. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported
Selling, general and administrative$m31.8Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$31.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure33.1Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$33.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-03-03, accession 0001326110-25-000033. Derived: 12-month figure less the 9-month figure.Report this figure41.9Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$41.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-05-09, accession 0001326110-24-000064.Report this figure49.3Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$49.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-08-12, accession 0001326110-24-000103.Report this figure35.9Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$35.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure41.7Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$41.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-03-03, accession 0001326110-25-000033. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported
Operating income$m(80.1)Operating income, Q3 FY2023, three months to 2023-09-30−$80.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure(85.4)Operating income, Q4 FY2023, three months to 2023-12-31−$85.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(95.2)Operating income, Q1 FY2024, three months to 2024-03-31−$95.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure(99.3)Operating income, Q2 FY2024, three months to 2024-06-30−$99.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure(80.3)Operating income, Q3 FY2024, three months to 2024-09-30−$80.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure(69.4)Operating income, Q4 FY2024, three months to 2024-12-31−$69.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(64.4)Operating income, Q1 FY2025, three months to 2025-03-31−$64.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(71.3)Operating income, Q2 FY2025, three months to 2025-06-30−$71.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure(55.6)Operating income, Q3 FY2025, three months to 2025-09-30−$55.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure(64.7)Operating income, Q4 FY2025, three months to 2025-12-31−$64.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(69.8)Operating income, Q1 FY2026, three months to 2026-03-31−$69.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(61.7)Operating income, Q2 FY2026, three months to 2026-06-30−$61.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Interest expense$m35.0Interest expense, Q3 FY2023, three months to 2023-09-30$35.0m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure31.8Interest expense, Q4 FY2023, three months to 2023-12-31$31.8m. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure29.5Interest expense, Q1 FY2024, three months to 2024-03-31$29.5m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure29.8Interest expense, Q2 FY2024, three months to 2024-06-30$29.8m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure29.3Interest expense, Q3 FY2024, three months to 2024-09-30$29.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure26.0Interest expense, Q4 FY2024, three months to 2024-12-31$26.0m. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure15.3Interest expense, Q1 FY2025, three months to 2025-03-31$15.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure15.5Interest expense, Q2 FY2025, three months to 2025-06-30$15.5m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure15.3Interest expense, Q3 FY2025, three months to 2025-09-30$15.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure14.8Interest expense, Q4 FY2025, three months to 2025-12-31$14.8m. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure(0.0)Income tax, Q4 FY2023, three months to 2023-12-31−$40.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(0.2)Income tax, Q1 FY2025, three months to 2025-03-31−$234.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure0.3Income tax, Q2 FY2025, three months to 2025-06-30$269.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure(0.0)Income tax, Q3 FY2025, three months to 2025-09-30−$35.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure(0.1)Income tax, Q4 FY2025, three months to 2025-12-31−$135.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$9.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Net income$m(95.6)Net income, Q3 FY2023, three months to 2023-09-30−$95.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure(233)Net income, Q4 FY2023, three months to 2023-12-31−$233.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(134)Net income, Q1 FY2024, three months to 2024-03-31−$134.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure(135)Net income, Q2 FY2024, three months to 2024-06-30−$134.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure(85.7)Net income, Q3 FY2024, three months to 2024-09-30−$85.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure(59.2)Net income, Q4 FY2024, three months to 2024-12-31−$59.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(130)Net income, Q1 FY2025, three months to 2025-03-31−$129.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(92.6)Net income, Q2 FY2025, three months to 2025-06-30−$92.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure(67.3)Net income, Q3 FY2025, three months to 2025-09-30−$67.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure(61.9)Net income, Q4 FY2025, three months to 2025-12-31−$61.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(633)Net income, Q1 FY2026, three months to 2026-03-31−$632.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(230)Net income, Q2 FY2026, three months to 2026-06-30−$230.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Diluted EPS$ per share(0.19)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figurenot reported(0.20)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure(0.20)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure(0.14)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figurenot reported(0.15)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(0.10)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure(0.07)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figurenot reported(0.62)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(0.22)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Basic EPS$ per share(0.19)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figurenot reported(0.20)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure(0.20)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure(0.12)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figurenot reported(0.15)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(0.10)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure(0.07)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figurenot reported(0.62)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(0.22)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure

Balance sheet

Cash and equivalents$75.7m, Q2 FY2026
Shareholders' equity−$1.05bn, Q2 FY2026
ImmunityBio, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m178Cash and equivalents, Q3 FY2023, at 2023-09-30$178.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure265Cash and equivalents, FY2023, at 2023-12-31$265.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-23, accession 0001326110-26-000030.Report this figure133Cash and equivalents, Q1 FY2024, at 2024-03-31$133.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure130Cash and equivalents, Q2 FY2024, at 2024-06-30$130.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure112Cash and equivalents, Q3 FY2024, at 2024-09-30$112.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure143Cash and equivalents, FY2024, at 2024-12-31$143.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-23, accession 0001326110-26-000030.Report this figure60.7Cash and equivalents, Q1 FY2025, at 2025-03-31$60.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure138Cash and equivalents, Q2 FY2025, at 2025-06-30$137.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure60.2Cash and equivalents, Q3 FY2025, at 2025-09-30$60.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure88.3Cash and equivalents, FY2025, at 2025-12-31$88.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure205Cash and equivalents, Q1 FY2026, at 2026-03-31$205.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure75.7Cash and equivalents, Q2 FY2026, at 2026-06-30$75.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Current assets$m215Current assets, Q3 FY2023, at 2023-09-30$215.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001326110-23-000147.Report this figure294Current assets, FY2023, at 2023-12-31$294.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-03, accession 0001326110-25-000033.Report this figure196Current assets, Q1 FY2024, at 2024-03-31$195.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001326110-24-000064.Report this figure243Current assets, Q2 FY2024, at 2024-06-30$242.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0001326110-24-000103.Report this figure163Current assets, Q3 FY2024, at 2024-09-30$163.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure185Current assets, FY2024, at 2024-12-31$184.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-23, accession 0001326110-26-000030.Report this figure109Current assets, Q1 FY2025, at 2025-03-31$109.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure208Current assets, Q2 FY2025, at 2025-06-30$208.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure329Current assets, Q3 FY2025, at 2025-09-30$329.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure315Current assets, FY2025, at 2025-12-31$314.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure453Current assets, Q1 FY2026, at 2026-03-31$453.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure439Current assets, Q2 FY2026, at 2026-06-30$439.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Total assets$m432Total assets, Q3 FY2023, at 2023-09-30$432.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001326110-23-000147.Report this figure504Total assets, FY2023, at 2023-12-31$504.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-03, accession 0001326110-25-000033.Report this figure401Total assets, Q1 FY2024, at 2024-03-31$400.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001326110-24-000064.Report this figure444Total assets, Q2 FY2024, at 2024-06-30$444.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0001326110-24-000103.Report this figure365Total assets, Q3 FY2024, at 2024-09-30$364.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure383Total assets, FY2024, at 2024-12-31$382.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-23, accession 0001326110-26-000030.Report this figure304Total assets, Q1 FY2025, at 2025-03-31$303.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure402Total assets, Q2 FY2025, at 2025-06-30$402.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure519Total assets, Q3 FY2025, at 2025-09-30$519.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure502Total assets, FY2025, at 2025-12-31$501.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure647Total assets, Q1 FY2026, at 2026-03-31$646.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure629Total assets, Q2 FY2026, at 2026-06-30$628.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Current liabilities$m90.3Current liabilities, Q3 FY2023, at 2023-09-30$90.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001326110-23-000147.Report this figure58.3Current liabilities, FY2023, at 2023-12-31$58.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-03, accession 0001326110-25-000033.Report this figure53.8Current liabilities, Q1 FY2024, at 2024-03-31$53.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001326110-24-000064.Report this figure62.1Current liabilities, Q2 FY2024, at 2024-06-30$62.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0001326110-24-000103.Report this figure61.0Current liabilities, Q3 FY2024, at 2024-09-30$61.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure54.9Current liabilities, FY2024, at 2024-12-31$54.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-23, accession 0001326110-26-000030.Report this figure49.2Current liabilities, Q1 FY2025, at 2025-03-31$49.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure50.6Current liabilities, Q2 FY2025, at 2025-06-30$50.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure57.1Current liabilities, Q3 FY2025, at 2025-09-30$57.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure61.8Current liabilities, FY2025, at 2025-12-31$61.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure68.0Current liabilities, Q1 FY2026, at 2026-03-31$68.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure76.7Current liabilities, Q2 FY2026, at 2026-06-30$76.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Total liabilities$m843Total liabilities, Q3 FY2023, at 2023-09-30$843.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001326110-23-000147.Report this figure1,090Total liabilities, FY2023, at 2023-12-31$1.09bn. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-03, accession 0001326110-25-000033.Report this figure1,092Total liabilities, Q1 FY2024, at 2024-03-31$1.09bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001326110-24-000064.Report this figure1,142Total liabilities, Q2 FY2024, at 2024-06-30$1.14bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-12, accession 0001326110-24-000103.Report this figure1,109Total liabilities, Q3 FY2024, at 2024-09-30$1.11bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure871Total liabilities, FY2024, at 2024-12-31$871.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-23, accession 0001326110-26-000030.Report this figure894Total liabilities, Q1 FY2025, at 2025-03-31$894.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure972Total liabilities, Q2 FY2025, at 2025-06-30$971.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure1,042Total liabilities, Q3 FY2025, at 2025-09-30$1.04bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure1,001Total liabilities, FY2025, at 2025-12-31$1.00bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure1,516Total liabilities, Q1 FY2026, at 2026-03-31$1.52bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure1,674Total liabilities, Q2 FY2026, at 2026-06-30$1.67bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reported1.2Current portion of debt, FY2024, at 2024-12-31$1.2m. XBRL concept us-gaap:DebtCurrent. 10-K filed 2026-02-23, accession 0001326110-26-000030.Report this figurenot reportednot reported2.6Current portion of debt, Q3 FY2025, at 2025-09-30$2.6m. XBRL concept us-gaap:DebtCurrent. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure1.8Current portion of debt, FY2025, at 2025-12-31$1.8m. XBRL concept us-gaap:DebtCurrent. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure0.9Current portion of debt, Q1 FY2026, at 2026-03-31$884.0k. XBRL concept us-gaap:DebtCurrent. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figurenot reported
Shareholders' equity$m(412)Shareholders' equity, Q3 FY2023, at 2023-09-30−$411.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-09, accession 0001326110-23-000147.Report this figure(587)Shareholders' equity, FY2023, at 2023-12-31−$587.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-03-03, accession 0001326110-25-000033.Report this figure(692)Shareholders' equity, Q1 FY2024, at 2024-03-31−$692.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-05-09, accession 0001326110-24-000064.Report this figure(698)Shareholders' equity, Q2 FY2024, at 2024-06-30−$698.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-08-12, accession 0001326110-24-000103.Report this figure(745)Shareholders' equity, Q3 FY2024, at 2024-09-30−$745.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure(489)Shareholders' equity, FY2024, at 2024-12-31−$489.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-23, accession 0001326110-26-000030.Report this figure(591)Shareholders' equity, Q1 FY2025, at 2025-03-31−$591.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure(571)Shareholders' equity, Q2 FY2025, at 2025-06-30−$570.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure(524)Shareholders' equity, Q3 FY2025, at 2025-09-30−$524.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure(500)Shareholders' equity, FY2025, at 2025-12-31−$500.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure(870)Shareholders' equity, Q1 FY2026, at 2026-03-31−$870.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(1,047)Shareholders' equity, Q2 FY2026, at 2026-06-30−$1.05bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure

Cash flow

Operating cash flow−$66.5m, Q2 FY2026
Capital expenditure$3.5m, Q2 FY2026
ImmunityBio, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(87.4)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$87.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001326110-24-000111. Derived: 9-month figure less the 6-month figure.Report this figure(115)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$115.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(107)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$107.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure(100)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$100.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0001326110-25-000114. Derived: 6-month figure less the 3-month figure.Report this figure(98.8)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$98.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001326110-25-000139. Derived: 9-month figure less the 6-month figure.Report this figure(85.1)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$85.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(85.9)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$85.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(79.7)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$79.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001326110-26-000079. Derived: 6-month figure less the 3-month figure.Report this figure(68.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$68.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001326110-25-000139. Derived: 9-month figure less the 6-month figure.Report this figure(70.4)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$70.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure(75.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$75.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure(66.5)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$66.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001326110-26-000079. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m5.7Capital expenditure, Q3 FY2023, three months to 2023-09-30$5.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001326110-24-000111. Derived: 9-month figure less the 6-month figure.Report this figure8.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$8.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure1.3Capital expenditure, Q1 FY2024, three months to 2024-03-31$1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure0.7Capital expenditure, Q2 FY2024, three months to 2024-06-30$724.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-05, accession 0001326110-25-000114. Derived: 6-month figure less the 3-month figure.Report this figure2.8Capital expenditure, Q3 FY2024, three months to 2024-09-30$2.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001326110-25-000139. Derived: 9-month figure less the 6-month figure.Report this figure2.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure1.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure1.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0001326110-26-000079. Derived: 6-month figure less the 3-month figure.Report this figure0.7Capital expenditure, Q3 FY2025, three months to 2025-09-30$741.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001326110-25-000139. Derived: 9-month figure less the 6-month figure.Report this figure0.9Capital expenditure, Q4 FY2025, three months to 2025-12-31$903.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001326110-26-000030. Derived: 12-month figure less the 9-month figure.Report this figure1.8Capital expenditure, Q1 FY2026, three months to 2026-03-31$1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure3.5Capital expenditure, Q2 FY2026, three months to 2026-06-30$3.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0001326110-26-000079. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)1.05bn, Q2 FY2026
ImmunityBio, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares400Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30400,059,707 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001326110-23-000147.Report this figure428Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31428,381,485 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001326110-24-000064.Report this figure437Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30437,456,657 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-12, accession 0001326110-24-000103.Report this figure498Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30498,375,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001326110-24-000111.Report this figure673Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31672,831,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001326110-25-000071.Report this figure687Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30686,938,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0001326110-25-000114.Report this figure698Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30697,961,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure853Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31853,162,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure888Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30888,216,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure947Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30946,601,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001326110-25-000139.Report this figure1,027Diluted shares (weighted), Q1 FY2026, three months to 2026-03-311,026,874,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001326110-26-000059.Report this figure1,050Diluted shares (weighted), Q2 FY2026, three months to 2026-06-301,050,070,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure

Shares outstanding: 1.06bnShares outstanding, period not labelled, at 2026-07-311,059,836,273 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-04, accession 0001326110-26-000079.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. Listed shows no prices and gives no investment advice.